focus -WSS

focus

author：leisure time 2025-09-30 01:02:05 - browse：4

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Paxlovid rebound happens. Why and to whom are still a mystery

WSS

Restaurant meals are packed with calories, and we still keep eating them

CRISPR pioneers react to Casgevy, first gene

Poor hospice wound care hurts patients and families

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Google's generative AI to analyze medical images — and talk to docs

explore

focus

explore

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Wegovy, Zepbound and weight loss drugs that preserve muscle

New air purifier tech could be key to improving indoor air quality

Morphosys mixed study results for blood cancer drug

After affirmative action ruling, medical educators look to 'holistic review'

Childhood cancer progress stalls for Black, Hispanic kids: Report

Virginia high school admissions case could be legal follow

Election results set back Medicaid expansion plans

explore

Restaurant meals are packed with calories, and we still keep eating them

Slovenia has suffered its worst

Congress must reauthorize a committee to support older Americans

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Gain of function research would be limited under House proposal

With heat waves through August, officials warn of health risks

hotspot

hotspot

focus

explore